Zhejiang Yatai Pharmaceutical Co., Ltd. (SHE:002370)
China · Delayed Price · Currency is CNY 5.16
+0.06 (1.18%)
Sep 30, 2026, 3:04 PM CST
SHE:002370 Financials Overview
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Revenue Revenue Growth | 328.58 | 323.14 | 405.17 | 420.64 | 373.44 | 315.13 |
Revenue Growth | -2.01% | -20.25% | -3.68% | 12.64% | 18.50% | -38.80% |
Gross Profit Gross Profit Growth | 102.61 | 94.78 | 120.75 | 132.1 | 126.22 | 104.89 |
Operating Income Operating Income Growth | -10.39 | -28.78 | -9.01 | -33.01 | -35.99 | -131.13 |
Net Income Net Income Growth | -9.3 | 96.31 | 34.24 | -11.88 | -132.69 | -228.28 |
Earnings Per Share EPS Growth | -0.01 | 0.13 | 0.05 | -0.02 | -0.25 | -0.43 |
EPS Growth | - | 160.00% | - | - | - | - |
| Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 |
Antibiotic Products Antibiotic Products Growth | 172.6 | 264.31 | 285.36 | 244.49 |
Non-Antibiotic Non-Antibiotic Growth | 148.79 | 137.6 | 131.56 | 127.93 |
Unallocated Other Operating Income Unallocated Other Operating Income Growth | 1.75 | 3.27 | 3.72 | 0.58 |
Total Total Growth | 323.14 | 405.17 | 420.64 | 373.44 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Cash & Investments Cash & Investments Growth | 515.38 | 618.72 | 743.85 | 720.47 | 757.62 | 821.11 |
Total Debt Total Debt Growth | - | - | 331.75 | 689.54 | 951.78 | 974.43 |
Net Cash (Debt) Net Cash Growth | 515.38 | 618.72 | 412.1 | 30.94 | -194.16 | -153.31 |
Net Cash Growth | -17.56% | 50.14% | 1232.00% | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | 0.70 | 0.84 | 0.60 | 0.05 | -0.37 | -0.29 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Cash Flow Operating Cash Flow Growth | -67.21 | 28.9 | 24.35 | 14.65 | 12.04 | -3.84 |
Capital Expenditures CapEx Growth | -9.95 | -5.05 | -9.92 | -7.46 | -21.1 | -15.78 |
Free Cash Flow Free Cash Flow Growth | -77.16 | 23.84 | 14.44 | 7.19 | -9.06 | -19.62 |
Free Cash Flow Growth | - | 65.18% | 100.70% | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Gross Margin | 31.23% | 29.33% | 29.80% | 31.40% | 33.80% | 33.28% |
Operating Margin | -3.16% | -8.91% | -2.22% | -7.85% | -9.64% | -41.61% |
Pretax Margin | -3.01% | 29.84% | 8.51% | -2.75% | -36.24% | -71.13% |
Profit Margin | -2.83% | 29.80% | 8.45% | -2.82% | -35.53% | -72.44% |
FCF Margin | -23.48% | 7.38% | 3.56% | 1.71% | -2.43% | -6.23% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Oct '26 Oct 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | - | 56.60 | 63.50 | - | - | - |
Forward PE | - | 39.30 | 39.30 | 39.30 | 39.30 | 39.30 |
P/FCF Ratio | - | 228.61 | 150.61 | 336.67 | - | - |
PS Ratio | 11.71 | 16.87 | 5.37 | 5.76 | 7.07 | 7.63 |